Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Hiu Ting Chan"'
Autor:
Kazumi Okamura, Satoshi Nagayama, Tomohiro Tate, Hiu Ting Chan, Kazuma Kiyotani, Yusuke Nakamura
Publikováno v:
Journal of Translational Medicine, Vol 20, Iss 1, Pp 1-14 (2022)
Abstract Background Tumor-draining lymph nodes (TDLNs) are primary sites, where anti-tumor lymphocytes are primed to tumor-specific antigens and play pivotal roles in immune responses against tumors. Although adoptive cell therapy (ACT) using lymphoc
Externí odkaz:
https://doaj.org/article/faa5c078156246d4af519e154cc2a97d
Autor:
Hiu Ting Chan, Satoshi Nagayama, Masumi Otaki, Yoon Ming Chin, Yosuke Fukunaga, Masashi Ueno, Yusuke Nakamura, Siew-Kee Low
Publikováno v:
Frontiers in Oncology, Vol 12 (2023)
IntroductionCirculating tumor DNA (ctDNA) has been increasingly recognized as a promising minimally-invasive biomarker that could identify patients with minimal residual disease and a high risk of recurrence after definitive treatment. In this study,
Externí odkaz:
https://doaj.org/article/147e9c2fdf894d1b8b75861d5a3c8aa5
Autor:
Hiu Ting Chan, Satoshi Nagayama, Yoon Ming Chin, Masumi Otaki, Rie Hayashi, Kazuma Kiyotani, Yosuke Fukunaga, Masashi Ueno, Yusuke Nakamura, Siew‐Kee Low
Publikováno v:
Molecular Oncology, Vol 14, Iss 8, Pp 1719-1730 (2020)
As the use of next‐generation sequencing (NGS) for plasma cell‐free DNA (cfDNA) continues to expand in clinical settings, accurate identification of circulating tumor DNA mutations is important to validate its use in the clinical management for c
Externí odkaz:
https://doaj.org/article/c7ba8e1582eb4f97ae1453d272fe05a8
Publikováno v:
Cancers, Vol 14, Iss 13, p 3275 (2022)
Genomic profiling using tumor biopsies remains the standard approach for the selection of approved molecular targeted therapies. However, this is often limited by its invasiveness, feasibility, and poor sample quality. Liquid biopsies provide a less
Externí odkaz:
https://doaj.org/article/dca3c378b59f40acb5f0579f70a6ea5a
Publikováno v:
Oncology and Therapy, Vol 7, Iss 1, Pp 1-32 (2019)
Abstract Cancer pharmacogenomics is the science concerned with understanding genetic alterations and its effects on the pharmacokinetics and pharmacodynamics of anti-cancer drugs, with the aim to provide cancer patients with the precise medication th
Externí odkaz:
https://doaj.org/article/851cf856e6fe4ae2a13577357e2fe242
Publikováno v:
Nanomaterials, Vol 11, Iss 7, p 1792 (2021)
Toxic heavy metal contamination in food and water from environmental pollution is a significant public health issue. Heavy metals do not biodegrade easily yet can be enriched hundreds of times by biological magnification, where toxic substances move
Externí odkaz:
https://doaj.org/article/8b22e06b46bf4c2a95746b98d34c2181
Publikováno v:
Cancers, Vol 12, Iss 8, p 2277 (2020)
The use of blood liquid biopsy is being gradually incorporated into the clinical setting of cancer management. The minimally invasive nature of the usage of cell-free DNA (cfDNA) and its ability to capture the molecular alterations of tumors are grea
Externí odkaz:
https://doaj.org/article/3521f1d262f4485bb64602d0020d48c5
Autor:
Siew-Kee, Low, Ryo, Ariyasu, Ken, Uchibori, Rie, Hayashi, Hiu Ting, Chan, Yoon Ming, Chin, Takahiro, Akita, Yuhei, Harutani, Ayu, Kiritani, Ryosuke, Tsugitomi, Ryo, Manabe, Shinsuke, Ogusu, Yoshiaki, Amino, Satoru, Kitazono, Noriko, Yanagitani, Yusuke, Nakamura, Makoto, Nishio
Publikováno v:
Transl Lung Cancer Res
BACKGROUND: Genomic profiling of tumors from cancer patients facilitates molecular-guided therapy. The turnaround time is one of important issues to deliver results timely for clinical decisions. The Ion Torrent™ Genexus™ Integrated Sequencer aut
Autor:
Yoon Ming Chin, Tomoko Shibayama, Hiu Ting Chan, Masumi Otaki, Fumikata Hara, Takayuki Kobayashi, Kokoro Kobayashi, Mari Hosonaga, Ippei Fukada, Lina Inagaki, Makiko Ono, Yoshinori Ito, Shunji Takahashi, Shinji Ohno, Takayuki Ueno, Yusuke Nakamura, Siew‐Kee Low
Publikováno v:
Cancer science. 113(5)
Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) significantly improve progression-free survival and have become the standard therapy for estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer patients.
Publikováno v:
183rd Meeting of the Acoustical Society of America.